 Overview |
 Search Downloads |
 Submit file |
 Up |
| Category: Science of Skin |
|
|
 What is Skin? Information Sheet Version:1.0 
|
|
 An overview of human skin, designed to accompany our "What is skin?" webcast video. Learn about the layers of skin. |
Created Size Downloads |
2012-04-17 10:39:01 707.99 KB 355 |
||
| Actinic prurigo Information Sheet Version:1.0
|
|
 An overview of actinic Prurigo (AP), a rare chronic, idiopathic skin condition, which is characterised by abnormal cutaneous responses to ultraviolet radiation. |
Created Size Downloads |
2012-05-10 15:39:55 682.34 KB 163 |
||
| Erythropoietic Protoporphyria Information Sheet Version:1.1
|
|
 An overview of erythropoietic protoporphyria (EPP), a rare intolerance to light. Developed in conjunction with the EPP community via Clinuvel's Photoprotection Network on Facebook. |
Created Size Downloads |
2012-05-10 15:30:26 358.34 KB 196 |
||
Clinuvel Blog Posts
The biennial Porphyrins & Porphyrias conference is the only international meeting of global key opinion leaders on the group of...
Read More
Today, February 28, marks Rare Disease Day: an annual event to help highlight the effects of rare diseases on individuals, families and the...
Read MoreWe've just released the first results from our vitiligo program which you can view online here. Following their release, we expect a number...
Read MoreClinuvel Webcasts
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut... Watch now |
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut... Watch now |
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut... Watch now |
Clinuvel Spotlight
The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology and has spent over A$20million optimising the chemistry of afamelanotide (the active ingredient in SCENESSE®) an... Read more |
